Physician profile
David C Hoffman
NPI 1245332881
$1,444.33
in general payments reported to CMS, 2019-2025
26 companies · $371 in 2025
The $371 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $145 · 2022: $132 · 2023: $217 · 2024: $378 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $964.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $199.15 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $164.94 | 2019-2024 | Jornay Pm |
| Welch Allyn | $128.13 | 2020 | |
| Novo Nordisk INC | $120.89 | 2019-2025 | Wegovy, Saxenda |
| E.R. Squibb & Sons, L.L.C. | $92.77 | 2019 | |
| Pfizer INC. | $75.92 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $71.94 | 2022-2024 | Gardasil, Vaxelis, Gardasil 9 |
| Abbvie INC. | $63.84 | 2019-2024 | |
| Heartflow, INC. | $50.14 | 2024 | |
| Amgen INC. | $49.22 | 2019-2025 | Evenity |
| Supernus Pharmaceuticals, INC. | $47.62 | 2022-2023 | Qelbree |
| Collegium Pharmaceutical, INC. | $45.81 | 2025 | Jornay Pm |
| Lilly USA, LLC | $45.53 | 2024 | Zepbound, Mounjaro, Basaglar |
| Sanofi-Aventis U.S. LLC | $45.37 | 2022-2023 | |
| Exact Sciences Corporation | $35.54 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $23.71 | 2024-2025 | Heplisav-B |
| Aimmune Therapeutics, INC. | $22.49 | 2025 | Zenpep |
| Astrazeneca Pharmaceuticals Lp | $22.22 | 2025 | Farxiga |
| Axsome Therapeutics, INC. | $22.00 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $21.80 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.63 | 2025 | Caplyta |
| Medtronic, INC. | $17.43 | 2025 | Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.32 | 2025 | Xifaxan |
| Tris Pharma INC | $16.57 | 2020 | |
| Hologic Sales and Service, LLC | $15.41 | 2022 | |
| Mayne Pharma Commercial LLC | $6.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.